GD-11 is a blood-brain barrier (BBB)-targeting HIF-1α inhibitor, and capable of exerting potent neuroprotective effects in stroke lesions. Stroke is the leading cause of death and disability among adults in China. GD-11's dual-targeting properties endow it with brain-targeted delivery and neuroprotective functions, demonstrating good therapeutic effects in acute stroke patients across all clinical stages.

GD-19 is the optically active isomer of an arylpropionic acid-based anti-inflammatory and analgesic agent. It is designed to selectively accumulate at sites of inflammation, tissue injury (including post-surgical, chemotherapy-induced, or radiotherapy-related damage), infection, and nerve infiltration, thereby maximizing its therapeutic efficacy while minimizing systemic exposure and adverse effects.

GD-20 demonstrates broad immunomodulatory, neuroprotective, and analgesic efficacy across multiple preclinical models, including inhibition of T and B cell proliferation, downregulation of T cell-mediated responses, reduction of pro-inflammatory cytokines production, protection against oxidative stress-induced neuronal damage, and amelioration of disease severity in experimental autoimmune encephalomyelitis (EAE).

GD-20 has successfully completed Phase I clinical trials, demonstrating favorable safety, tolerability, and pharmacokinetic profiles that support progression to Phase II development in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.

GD-25 is a selective NaV1.8 inhibitor for acute and chronic pain by AI-Driven Design, and currently advancing toward IND-enabling studies. GD-25 possess stronger efficacy than FDA approved drug Suzetrigine while holding a simple but unique molecular structure. All in vitro and in vivo results from preclinical studies of GD-25 demonstrate superior efficacy, pharmacokinetic, and safety profiles compared to VX-548.